19 completed, 9 unknown, 6 active not recruiting, 5 recruiting. 46 Phase 3, 7 Phase 2.
Follow Small Cell Lung Cancer: new trials by email Literature Review of Small Cell Lung Cancer trials Research Report on Small Cell Lung Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Gocatamig (MK-6070) With Durvalumab in Participants With Small Cell Lung Cancer (MK-6070-004) Gocatamig, Durvalumab, Rescue Medications - Small Cell Lung Cancer | Phase 3 | Not yet recruiting | Merck Sharp & Dohme LLC | 564 | 2026-12-07 | 2026-11-02 |
| Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC) Tarlatamab - Small Cell Lung Cancer | Phase 3 | Recruiting | Amgen | 400 | 2026-08-28 | 2026-09-17 |
| QL1706 Plus Anlotinib as a Later-line Treatment for Patients With Advanced Lung Cancer QL1706, Anlotinib - Small Cell Lung Cancer | Phase 2 / Phase 3 | Not yet recruiting | Sun Yat-sen University | 120 | 2026-07-30 | 2026-06-09 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer ABBV-706, Topotecan, Lurbinectedin - Small Cell Lung Cancer | Phase 3 | Recruiting | AbbVie | 531 | 2026-07-02 | 2026-09-23 |
| Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polymorphisms ETOPOSIDE - Usual, ETOPOSIDE - Study - Small Cell Lung Cancer | Phase 2 / Phase 3 | Active not recruiting | Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair | 600 | 2025-07-16 | 2026-08-27 |
| A Study of AK112 as Consolidation Treatment for Patients With Limited Stage Small-cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy AK112, Placebo - Small Cell Lung Cancer | Phase 3 | Recruiting | Akeso | 560 | 2025-06-13 | 2026-03-05 |
| Immunonutrition Reduces Acute Esophagitis After Thoracic Radiotherapy in Lung Cancer Oral immunonutrition - Non Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | Recruiting | Hunan Cancer Hospital | 121 | 2025-02-25 | 2026-04-02 |
| A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer (TAISHAN-302) YL201, topotecan hydrochloride for injection - Small Cell Lung Cancer | Phase 3 | Active not recruiting | MediLink Therapeutics (Suzhou) Co., Ltd. | 438 | 2024-12-17 | 2026-09-15 |
| JK-1201I Compared with Topotecan in Patients with Relapsed Extensive Stage Small Cell Lung Cancer JK-1201I, Topotecan - Small Cell Lung Cancer | Phase 3 | Not yet recruiting | JenKem Technology Co., Ltd. | 394 | 2024-09-16 | 2024-09-03 |
| A Study Comparing BL-B01D1 With Topotecan in Patients With Recurrent Small Cell Lung Cancer(PANKU-Lung03) BL-B01D1, Topotecan - Small Cell Lung Cancer | Phase 3 | Active not recruiting | Sichuan Baili Pharmaceutical Co., Ltd. | 722 | 2024-08-07 | 2026-04-17 |
| ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cell Lung Cancer HS-20093, Topotecan - Small Cell Lung Cancer | Phase 3 | Completed | Hansoh BioMedical R&D Company | 461 | 2024-07-04 | 2026-10-16 |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer Ifinatamab deruxtecan, Topotecan, Amrubicin - Small Cell Lung Cancer | Phase 3 | Recruiting | Daiichi Sankyo | 540 | 2024-05-21 | 2026-08-06 |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Tarlatamab, Placebo - Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer | Phase 3 | Active not recruiting | Amgen | 404 | 2024-02-20 | 2026-04-29 |
| Phase 3 Clinical Study of Chiauranib Capsule in Patients With Small-cell Lung Cancer Chiauranib, Placebo - Small Cell Lung Cancer | Phase 3 | Completed | Chipscreen Biosciences, Ltd. | 184 | 2021-03-05 | 2024-12-09 |
| Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013) Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline) - Small Cell Lung Cancer | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 672 | 2020-12-08 | 2026-09-24 |
| Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. Camrelizumab combined with Apatinib, Etoposide and Cisplatin - Lung Neoplasm, Small Cell Lung Cancer | Phase 3 | Unknown | Fuzhou General Hospital | 45 | 2020-08-01 | 2021-02-08 |
| A Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Patients With Untreated Extensive-Stage Small Cell Lung Cancer Tiragolumab, Atezolizumab, Carboplatin - Small Cell Lung Cancer | Phase 3 | Completed | Hoffmann-La Roche | 490 | 2020-02-04 | 2026-04-03 |
| Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer Anlotinib, Placebos, Topotecan - Small Cell Lung Cancer | Phase 3 | Unknown | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 184 | 2019-10-31 | 2019-08-29 |
| Toripalimab in Combination With Platinum Plus Etoposidein Patients With Extensive-Stage Small Cell Lung Cancer TORIPALIMAB INJECTION(JS001 ) Carboplatin Cisplatin Etoposide Placebo - Small Cell Lung Cancer | Phase 3 | Completed | Shanghai Junshi Bioscience Co., Ltd. | 442 | 2019-07-23 | 2025-01-16 |
| Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer Tislelizumab, Cisplatin, Carboplatin - Small Cell Lung Cancer | Phase 3 | Completed | BeiGene | 457 | 2019-07-22 | 2025-02-28 |
Showing 20 of 46. Sign in to see all of them.
Small Cell Lung Carcinoma (46) · Lung Neoplasms (5) · Neoplasms (5) · Carcinoma, Non-Small-Cell Lung (2) · Neoplasm Metastasis (2) · Anxiety Disorders (1) · Bile Duct Neoplasms (1) · Carcinoma (1) · Depression (1) · Esophageal Neoplasms (1) · Esophagitis (1) · Liver Neoplasms (1) · Mesothelioma, Malignant (1) · Pancreatic Neoplasms (1) · Parkinson Disease 4, Autosomal Dominant Lewy Body (1)
Bronchial Neoplasms (46) · Carcinoma, Bronchogenic (46) · Lung Diseases (46) · Neoplasms by Site (46) · Respiratory Tract Diseases (46) · Respiratory Tract Neoplasms (46) · Thoracic Neoplasms (46) · Lung Neoplasms (41) · Neoplasms (41) · Digestive System Diseases (2) · Esophageal Diseases (2) · Gastrointestinal Diseases (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Neoplastic Processes (2)
Topotecan (14) · Cisplatin (9) · Etoposide (9) · Carboplatin (6) · Dexamethasone (3) · Irinotecan (3) · amrubicin (3) · rovalpituzumab tesirine (3) · AMG 757 (2) · PM 01183 (2) · anlotinib (2) · apatinib (2) · durvalumab (2) · 2,2',4,4',5-pentachlorodiphenyl ether (1) · BID protein, human (1)
AbbVie (4) · Amgen (3) · Merck Sharp & Dohme LLC (2) · Akeso (1) · Alliance for Clinical Trials in Oncology (1) · AstraZeneca (1) · BeiGene (1) · Beijing Chest Hospital (1) · Celgene (1) · Changzhou Cancer Hospital of Soochow University (1) · Charite University, Berlin, Germany (1) · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (1) · Chipscreen Biosciences, Ltd. (1) · Clinical Research Center for Solid Tumor, Korea (1) · Daiichi Sankyo (1)
China (21) · United States (18) · Belgium (14) · France (14) · Germany (14) · Italy (14) · Spain (14) · Australia (13) · Poland (13) · South Korea (13) · Hungary (12) · United Kingdom (12) · Brazil (11) · Russia (11) · Netherlands (10)
Li Zhang (2) · Cesare Gridelli, M.D. (1) · Ciro Gallo, M.D., Ph.D (1) · Dae Seog Heo, MD, PhD (1) · Dr. Hazel Breitz, M.D. (1) · Francesco Perrone, M.D., Ph.D (1) · Haiyi Jiang, M.D. (1)
PMID 29290251, PMID 36184621, PMID 39113428, PMID 18467726, PMID 19720897, PMID 25688059, PMID 28097515, PMID 28625627, PMID 29106448, PMID 31948903, PMID 32031887, PMID 32888454, PMID 33509647, PMID 34589918, PMID 34632876, PMID 35195913, PMID 35278766, PMID 35613997, PMID 37976444, PMID 38460751, PMID 38648575, PMID 39268857, PMID 39541202, PMID 39615412, PMID 39738721, PMID 40976711, PMID 41055143, PMID 41614649, PMID 41796863, PMID 41921748, PMID 42497381, PMID 42734213, PMID 42806195
2023 (3), 2016 (2), 2017 (2), 2019 (2), 2009 (1), 2018 (1), 2025 (1), U10CA037447 (1), UG1CA189823 (1)